Evidence map›Paper›PMID 32747748›Full record

ArticleBritish journal of cancer2020

Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease.

Michael B Ware, Mohammad Y Zaidi, Jennifer Yang, Michael K Turgeon, Alyssa Krasinskas, Thomas A Mace, Kaitlin Keenan, Matthew R Farren, Amanda N Ruggieri, Yiman Li and 9 more

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Long Non-Coding RNA LINC01123 Facilitates Cholangiocarcinoma Aggravation by Targeting miR-641.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Michael B WareDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Mohammad Y ZaidiDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Jennifer YangDivisions of Medical Oncology and Gastroenterology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Michael K TurgeonDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Alyssa KrasinskasDepartment of Pathology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Thomas A MaceDivisions of Medical Oncology and Gastroenterology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Kaitlin KeenanDivisions of Medical Oncology and Gastroenterology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Matthew R FarrenDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Amanda N RuggieriDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Yiman LiBiostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Chao ZhangBiostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Zhengjia ChenBiostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Gregory S YoungCenter for Biostatistics, The Ohio State University, Columbus, OH, USA.
Omar ElnaggarDivisions of Medical Oncology and Gastroenterology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Zheng CheDivisions of Medical Oncology and Gastroenterology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Shishir K MaithelDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Tanios Bekaii-SaabMayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA.
Bassel El-RayesDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Gregory B LesinskiDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA. gregory.b.lesinski@emory.edu.ORCID http://orcid.org/0000-0002-8787-7678
Emory University · USThe Ohio State University · USWinnMed · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
Tumor ImmunologyT32CA090223 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2023
$4.1M
Targeting immune stroma interactions in pancreatic cancerR01CA228406 · NCI · EMORY UNIVERSITY · PI EL-RAYES, BASSEL, LESINSKI, GREGORY B. · 2019 to 2023
$1.7M
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinomaR01CA228414 · NCI · EMORY UNIVERSITY · PI AZAD, NILOFER S., LESINSKI, GREGORY B. · 2018 to 2021
$1.6M
Enhancing immune therapy in pancreatic cancer by targeting IL-6R01CA208253 · NCI · OHIO STATE UNIVERSITY · PI LESINSKI, GREGORY B. · 2016 to 2021
$1.6M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA208253NCI NIH HHS R01 CA228406NCI NIH HHS R01 CA228414NCI NIH HHS T32 CA090223U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1R01 CA228414-01
6 · The paper itself

Abstract

backgroundBTC is an aggressive disease exacerbated by inflammation and immune suppression. Expansion of immunosuppressive cells occurs in biliary tract cancer (BTC), yet the role of BTC-derived cytokines in this process is unclear.

methodsActivated signalling pathways and cytokine production were evaluated in a panel of human BTC cell lines. Human peripheral blood mononuclear cells (PBMCs) were cultured with BTC supernatants, with and without cytokine neutralising antibodies, and analysed by flow cytometry or immunoblot. A human BTC tissue microarray (TMA, n = 69) was stained for IL-6, GM-CSF, and CD33

resultsImmunomodulatory factors (IL-6, GM-CSF, MCP-1) were present in BTC supernatants. BTC supernatants expanded CD33

conclusionBTC-derived factors promote suppressive myeloid cell expansion, and higher numbers of CD33

Indexed as

Biliary Tract NeoplasmsCalgranulin BCell CountCell ProliferationCells, CulturedCulture Media, ConditionedCytokinesHumansLymphocyte ActivationMyeloid CellsMyeloid-Derived Suppressor CellsNeoplasm GradingNeoplasm InvasivenessSialic Acid Binding Ig-like Lectin 3Calgranulin BCulture Media, ConditionedCytokinesSialic Acid Binding Ig-like Lectin 3

Identifiers

PMID32747748
PMCPMC7591861
OpenAlexW3046761132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.